UK Oncolytic Virus Therapy Market by Product (HSV-Based Oncolytic Viruses, Adenoviruses-Based Oncolytic Viruses, Vaccinia Virus-Based Oncolytic Viruses, Vesicular Stomatitis Virus-Based Oncolytic Viruses, Newcastle Disease Oncolytic Viruses, and Others), by Application (Prostate Cancer, Breast Cancer, Ovarian Cancer, Melanoma, and Others), and Forecast 2019-2025.
The UK oncolytic virus therapy market is estimated to grow at a CAGR of more than 13% during the forecast period. Research in the field of Oncolytic virus is still in its initial phase in UK. A second-generation oncolytic virus-based drug is registered in UK under the name of talimogene laherparepvec. Amgen Inc, Merck & Co., Inc. and Experimental Cancer Medicine Centre (ECMC) are few of the key organizations which are investing in the clinical trials involving oncolytic virus therapy in UK in collaboration with Cancer Research UK. In line with the strategy of developing treatment alternatives, the companies have introduced various clinical trials including the effect of talimogene laherparepvec on melanoma and head and neck cancers.
The UK oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.
The report covers the analysis of several players such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Merck and Co. Inc., Amgen Inc., Orca Therapeutics, OncoTheis, and others operating in the UK oncolytic virus therapy market. PsiOxus Therapeutics Ltd. is one of the companies headquartered in UK. The company is collaborating with other immuno-oncology companies in the market for the purpose of increasing their consumer base. In December 2017, the application for the clinical trial of NG-348 for the treatment of solid tumor was approved. For this, the Bristol Myers Squibb has paid $15 million to PsiOxus as a per the licensing agreement between the two firms. The two companies entered into strategic collaboration on Dec 2016, in which Bristol Myers granted $50 million to PsiOxus.
Research Methodology
The market study of the UK oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report is intended for pharmaceutical and biopharmaceutical companies, healthcare organizations, research institutes and academics, investing companies, potential investors, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. UK Oncolytic Virus Therapy Market Research and Analysis by Product
2. UK Oncolytic Virus Therapy Market Research and Analysis by Application
The UK oncolytic virus therapy market is estimated to grow at a CAGR of more than 13% during the forecast period. Research in the field of Oncolytic virus is still in its initial phase in UK. A second-generation oncolytic virus-based drug is registered in UK under the name of talimogene laherparepvec. Amgen Inc, Merck & Co., Inc. and Experimental Cancer Medicine Centre (ECMC) are few of the key organizations which are investing in the clinical trials involving oncolytic virus therapy in UK in collaboration with Cancer Research UK. In line with the strategy of developing treatment alternatives, the companies have introduced various clinical trials including the effect of talimogene laherparepvec on melanoma and head and neck cancers.
The UK oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.
The report covers the analysis of several players such as Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Merck and Co. Inc., Amgen Inc., Orca Therapeutics, OncoTheis, and others operating in the UK oncolytic virus therapy market. PsiOxus Therapeutics Ltd. is one of the companies headquartered in UK. The company is collaborating with other immuno-oncology companies in the market for the purpose of increasing their consumer base. In December 2017, the application for the clinical trial of NG-348 for the treatment of solid tumor was approved. For this, the Bristol Myers Squibb has paid $15 million to PsiOxus as a per the licensing agreement between the two firms. The two companies entered into strategic collaboration on Dec 2016, in which Bristol Myers granted $50 million to PsiOxus.
Research Methodology
The market study of the UK oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.
Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Authentic public databases such as the WHO, World Bank, and the National Institutes of Health.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report is intended for pharmaceutical and biopharmaceutical companies, healthcare organizations, research institutes and academics, investing companies, potential investors, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.
Market Segmentation:
1. UK Oncolytic Virus Therapy Market Research and Analysis by Product
2. UK Oncolytic Virus Therapy Market Research and Analysis by Application
Table of Contents
1. Report Summary
2. Market Overview and Insights
3. Competitive Landscape
4. Market Determinants
5. Market Segmentation
6. Company Profiles
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
A selection of companies mentioned in this report includes:
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche Ltd.
- Medigene AG
- Merck & Co., Inc.
- Orca Therapeutics B.V.
- OncoTheis
- PsiOxus Therapeutics Ltd.
- Targovax ASA
- Tilt Biotherapeutics Ltd.
- Transgene SA
- VCN Biosciences SL
